Skip to main content
AHN-GOOK PHARMACEUTICAL Co., Ltd. logo

AHN-GOOK PHARMACEUTICAL Co., Ltd. — Investor Relations & Filings

Ticker · 001540 ISIN · KR7001540004 KO Manufacturing
Open in API
Filings indexed 172 across all filing types
Latest filing 2026-05-14 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 001540

About AHN-GOOK PHARMACEUTICAL Co., Ltd.

https://www.no1health2.or.kr:19621/

AHN-GOOK PHARMACEUTICAL Co., Ltd. is a pharmaceutical company that develops, manufactures, and markets a broad range of medicines. The company has a strong focus on treatments for the respiratory system and cardiovascular diseases. Its product portfolio includes prescription drugs, over-the-counter medications, and health supplements, with notable products such as Synatura Syrup for respiratory conditions, as well as treatments for digestive and ophthalmic health. The company is dedicated to promoting human health and improving quality of life through the development of innovative and effective pharmaceutical solutions for a global market.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 94% confidence The document is titled ‘분기보고서’ covering the period January 1 to March 31, 2026, and contains comprehensive financial statements, business overview, operational details, and quantitative data for the quarter. It is not merely an announcement or a supplement but the full interim quarterly report itself, matching the definition of an ‘Interim / Quarterly Report’ (IR). Q1 2026
2026-05-14 Korean
생산중단
Regulatory Filings Classification · 95% confidence The document is a notification about the suspension of production activities for a specific product type (tablet formulation) due to regulatory violations (pharmaceutical law). It includes details such as the suspension period, affected sales figures, reasons for suspension, and future plans. The document is short (1246 characters) and serves as an official announcement of a regulatory action affecting the company's operations. It does not contain financial statements, audit information, or detailed management discussion. It is not a report or presentation but a regulatory announcement about production suspension. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-05-08 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 95% confidence The document is a Korean ‘주식등의 대량보유상황보고서(일반)’ – a large shareholding status report filed under the Capital Markets Act (capital market regulations). It details a change in major shareholdings of the issuer, including thresholds, ownership percentages, and related contracting. This corresponds exactly to a Major Shareholding Notification (MRQ).
2026-04-17 Korean
기업가치제고계획(자율공시)
Regulatory Filings Classification · 75% confidence The document is a Korean autonomous disclosure (“자율공시”) titled “기업가치 제고 계획,” a corporate value enhancement plan required under tax law. It outlines future product differentiation strategy and shareholder return policy including dividend targets, rather than reporting actual financial results or providing a report itself. It is not an earnings release, dividend notice alone, investor presentation, or standard financial report, but a regulatory announcement of strategic plans. It therefore falls into the general Regulatory Filings fallback category.
2026-03-27 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is a formal report detailing the results of an annual general shareholders’ meeting, including vote outcomes on financial statement approval, dividend resolutions, board and auditor elections, and amendments to the articles of incorporation. This matches the definition of “Declaration of Voting Results & Voting Rights Announcements” (Code: DVA).
2026-03-26 Korean
사업보고서 (2025.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for the 68th fiscal year (2025) of Ahn-Gook Pharmaceutical Co., Ltd. It contains comprehensive company information, financial data, management discussion, and governance details, which is the standard format for an Annual Report (10-K equivalent in the Korean regulatory context). FY 2025
2026-03-18 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.